Cargando…

New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder

Vortioxetine is a novel antidepressant with effects on multiple 5-HT receptors and on the serotonin transporter. This paper reviews preclinical and clinical evidence regarding its mechanism of action, its tolerability, and its efficacy in treating major depression. Clinical studies indicate that vor...

Descripción completa

Detalles Bibliográficos
Autores principales: Katona, Cornelius L, Katona, Cara P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933721/
https://www.ncbi.nlm.nih.gov/pubmed/24570588
http://dx.doi.org/10.2147/NDT.S39544
_version_ 1782304977402724352
author Katona, Cornelius L
Katona, Cara P
author_facet Katona, Cornelius L
Katona, Cara P
author_sort Katona, Cornelius L
collection PubMed
description Vortioxetine is a novel antidepressant with effects on multiple 5-HT receptors and on the serotonin transporter. This paper reviews preclinical and clinical evidence regarding its mechanism of action, its tolerability, and its efficacy in treating major depression. Clinical studies indicate that vortioxetine is effective in the treatment of major depression, though there is no suggestion of superiority over active comparators. There may be a clinically meaningful advantage in terms of tolerability.
format Online
Article
Text
id pubmed-3933721
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-39337212014-02-25 New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder Katona, Cornelius L Katona, Cara P Neuropsychiatr Dis Treat Review Vortioxetine is a novel antidepressant with effects on multiple 5-HT receptors and on the serotonin transporter. This paper reviews preclinical and clinical evidence regarding its mechanism of action, its tolerability, and its efficacy in treating major depression. Clinical studies indicate that vortioxetine is effective in the treatment of major depression, though there is no suggestion of superiority over active comparators. There may be a clinically meaningful advantage in terms of tolerability. Dove Medical Press 2014-02-19 /pmc/articles/PMC3933721/ /pubmed/24570588 http://dx.doi.org/10.2147/NDT.S39544 Text en © 2014 Katona and Katona. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Katona, Cornelius L
Katona, Cara P
New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
title New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
title_full New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
title_fullStr New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
title_full_unstemmed New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
title_short New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
title_sort new generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933721/
https://www.ncbi.nlm.nih.gov/pubmed/24570588
http://dx.doi.org/10.2147/NDT.S39544
work_keys_str_mv AT katonacorneliusl newgenerationmultimodalantidepressantsfocusonvortioxetineformajordepressivedisorder
AT katonacarap newgenerationmultimodalantidepressantsfocusonvortioxetineformajordepressivedisorder